A Nomogram Model for Evaluating the Risk of Lymph Node Metastasis in cT2-cT4N0M0 Gastric Cancer Population

09 May 2022: Clinical Research

Zibo Zhang ^ABCDEF , Yu Liu ^AE* , Guohong Ma ^BE , Jixuan Su ^B

DOI: 10.12659/MSM.935696

Med Sci Monit 2022; 28:e935696

Table 1 General information of patients in the 2 validation sets.

Variable	Internal validation set (n=236)				External validation set (n=100)
Variable	LNM(+) (n=108)	LNM(−) (n=128)	χ2	P	LNM(+) (n=50)	LNM(−) (n=50)	χ2	P
Age			0.294	0.587			0.184	0.66
	36	47			15	17
≥60	72	81			35	33
Gender			1.073	0.3			0.19	0.66
Male	79	101			34	36
Female	29	27			16	14
Tumor site			33.25				7.89	0.019
Cardia and stomach fundus	19	42			10	19
Gastic body	18	50			6	11
Gastric antrum	71	36			34	20
Degree of differentiation			38.54				16.64	0.002
Poorly differentiated	72	34			27	13
Poorly to moderately differentiated	15	33			13	12
Moderately differentiated	19	56			5	22
Moderately to well-differentiated	1	3			3	1
Well-differentiated	1	2			2	2
Lauren type			36.57				15.87
Intestinal type	19	69			8	27
Diffuse type	37	34			15	8
Mixed type	52	25			27	15
Depth of invation			44.59				27.30
T2	28	89			9	34
T3	4	2			2	1
T4a	69	34			34	12
T4b	7	3			5	3
Presence of ulcers			5.93	0.15			3.04	0.12
Yes	87	85			39	31
No	21	43			11	19
Presence of vascular thrombi			86.64				5.26	0.022
Yes	72	11			14	5
No	36	117			36	45
Tumor size (cm)	4.09±0.18	3.00±0.13	–		3.90±0.19	2.74±0.19	–
Ki67 (%)	56.38±17.10	44.22±20.78	–		55.80±2.26	47.72±3.16	–	0.041
CEA (ng/ml)	9.44±3.88	3.74±0.68	–	0.15	3.42±0.62	4.80±1.61	–	0.98
CA19-9 (u/ml)	24.28±4.49	14.30±2.52	–	0.045	19.07±5.33	18.97±5.35	–	0.42
CA72-4 (u/ml)	10.21±3.57	4.79±0.91	–	0.12	5.27±2.10	5.95±1.62	–	0.79
AFP (ng/ml)	10.22±3.57	3.61±0.52	–	0.07	4.14±0.49	3.18±0.19	–	0.077
LNM – lymph node metastasis; CEA – carcinoembryonic antigen; CA19-9 – carbohydrate antigen 19-9; CA72-4 – carbohydrate antigen 72-4; AFP – Alpha-fetoprotein.